

Marek Minarik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2689451/publications.pdf>

Version: 2024-02-01

106
papers

1,499
citations

279798

23
h-index

330143

37
g-index

108
all docs

108
docs citations

108
times ranked

2567
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Circulating Tumour DNA and ¹⁸ F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 270-281.	2.0	4
2	Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma. <i>Cancers</i> , 2022, 14, 2823.	3.7	0
3	Capillary Electrophoresis and its Basic Principles in Historical Retrospect Part 1. The Early Decades of the "Long Nineteenth Century": The Voltaic Pile, and the Discovery of Electrolysis, Electrophoresis and Electroosmosis. <i>Substantia</i> , 2021, 5, .	0.3	3
4	Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 379-385.	1.9	5
5	Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response. <i>Frontiers in Oncology</i> , 2020, 10, 1028.	2.8	25
6	Abstract A30: Dynamics of ctDNA may serve as an early predictor of response to nontargeted chemotherapy of advanced lung cancer patients. , 2020, , .		0
7	Abstract 724: Application of oncoMonitor [®] , ctDNA tracking technology for monitoring of therapy and early detection of recurrence in metastatic colorectal cancer. , 2020, , .		0
8	Current possibilities of predicting the therapeutic response to neoadjuvant chemoradiotherapy in rectal cancer. <i>Gastroenterologie A Hepatologie</i> , 2020, 74, 393-403.	0.1	1
9	Su1030 " Utility of Targeted Next-Generation Sequencing Panel for Comprehensive Focal Profiling of Dna Mutations in Tissue Samples of Patients with Ibd. <i>Gastroenterology</i> , 2019, 156, S-489.	1.3	0
10	P817 Profiles of somatic mutations in tissue of IBD and IBD-associated carcinomas revealed by a targeted next-generation sequencing (NGS) tumour panel confirm notable differences from sporadic colorectal carcinomas. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S531-S531.	1.3	0
11	Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. <i>World Journal of Gastroenterology</i> , 2019, 25, 6939-6948.	3.3	24
12	Abstract 412: Application of a serial liquid biopsy ctDNA assay for monitoring efficacy of anti-angiogenic lung cancer therapy. , 2019, , .		0
13	Abstract 405: Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients. , 2019, , .		0
14	Abstract 412: Application of a serial liquid biopsy ctDNA assay for monitoring efficacy of anti-angiogenic lung cancer therapy. , 2019, , .		0
15	High performance liquid chromatography column efficiency enhancement by zero dead volume recycling and practical approach using park and recycle arrangement. <i>Journal of Chromatography A</i> , 2018, 1554, 1-7.	3.7	3
16	Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors. <i>Journal of Separation Science</i> , 2018, 41, 2819-2827.	2.5	4
17	Capillary electrophoresis, a method for the determination of nucleic acid ligands covalently attached to quantum dots representing a donor of Förster resonance energy transfer. <i>Journal of Separation Science</i> , 2018, 41, 2961-2968.	2.5	6
18	Nucleic Acids Chromatographic and Electrophoretic Methods "f. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
19	Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. <i>Anticancer Research</i> , 2017, 37, 6469-6476.	1.1	11
20	Abstract B09: Molecular phenotyping of colorectal tumors in clinical practice: Assignment of extended prognostic subtypes by direct testing of endoscopic specimens. , 2017, , .		0
21	Abstract B24: The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA: Selected case studies. , 2017, , .		0
22	Validation of the denaturing capillary electrophoresis (DCE) assay for non-invasive liquid biopsy in lung carcinoma: A study of concordance with the cobas EGFR mutation test v2.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23040-e23040.	1.6	0
23	Inflammatory bowel disease and gastrointestinal malignancies – risks, incidence and management. <i>Gastroenterologie A Hepatologie</i> , 2017, 71, 388-393.	0.1	0
24	Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. <i>Neoplasma</i> , 2016, 63, 471-476.	1.6	40
25	Prognostic Importance of Cell Cycle Regulators Cyclin D1 (<i>CCND1</i>) and Cyclin-Dependent Kinase Inhibitor 1B (<i>CDKN1B</i> /p27) in Sporadic Gastric Cancers. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-8.	1.5	7
26	Su2005 Prospective Longitudinal Molecular Characterization of Colorectal Tumors Based on CIMP/MSI/BRAF/KRAS Classification: Comparison of Advanced Adenomas to Early and Late Carcinomas. <i>Gastroenterology</i> , 2016, 150, S608.	1.3	0
27	Su2028 KRAS Mutation Assay on EUS FNA Specimens From Patients With Pancreatic Mass. <i>Gastroenterology</i> , 2016, 150, S615.	1.3	0
28	The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 718-725.	1.0	46
29	Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 1273-1279.	1.4	11
30	Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. <i>World Journal of Gastroenterology</i> , 2016, 22, 4936.	3.3	6
31	Utility of a panel of gene mutations and amplifications for estimation of prognosis in patients with gastric cancer. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 244-251.	0.1	0
32	Abstract 3139: Liquid biopsy (ctDNA) testing in clinical management of solid cancers: 5-years of experience. , 2016, , .		0
33	Abstract 4943: Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis. , 2016, , .		1
34	Abstract A19: Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients. , 2016, , .		0
35	Abstract B18: Molecular cancer testing of KRAS and miR-21 from EUS-guided biopsies of pancreatic tissue: Utility of aspirates vs. cytology. , 2016, , .		0
36	Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. <i>Anticancer Research</i> , 2016, 36, 447-53.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. <i>Anticancer Research</i> , 2016, 36, 455-60.	1.1	9
38	Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. <i>Anticancer Research</i> , 2016, 36, 2459-65.	1.1	13
39	MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-11.	1.5	30
40	Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy. <i>Cardiology</i> , 2015, 130, 137-142.	1.4	3
41	Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. <i>Tumor Biology</i> , 2015, 36, 5801-5805.	1.8	29
42	High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. <i>Tumor Biology</i> , 2015, 36, 9215-9222.	1.8	17
43	Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-654.	1.6	2
44	Evaluation of circulating-tumor DNA (ctDNA) as a source material for molecular phenotyping of colorectal tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 642-642.	1.6	0
45	Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3594-3594.	1.6	0
46	Abstract 5237: Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases. , 2015, , .		0
47	Abstract 2406: Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers. , 2015, , .		0
48	Erlotinib in the treatment of advanced squamous cell NSCLC. <i>Neoplasma</i> , 2014, 60, 676-682.	1.6	2
49	149 Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2014, 50, 51.	2.8	0
50	Colorectal cancer prevention in the Czech Republic. <i>European Journal of Cancer Prevention</i> , 2014, 23, 18-26.	1.3	29
51	Sa1386 EUS-Guided Biopsies for Molecular Testing of Pancreatic Cancer: Optimization of Experimental Parameters for DNA and miRNA Extraction and Analysis. <i>Gastroenterology</i> , 2014, 146, S-280.	1.3	0
52	Tu1889 A Long-Term Follow-Up of Patients With Recurring Sporadic Polyps: Is There a Benefit From Mutation Testing of Adenomatous Tissue?. <i>Gastroenterology</i> , 2014, 146, S-864-S-865.	1.3	0
53	Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats. <i>Human Mutation</i> , 2014, 35, 1021-1032.	2.5	151
54	Retreatment with Erlotinib of a Patient with Metastatic NSCLC Harboring EGFR Mutation: A Case Report. <i>Tumori</i> , 2014, 100, e70-e73.	1.1	1

#	ARTICLE	IF	CITATIONS
55	Colorectal cancer screening: 20 years of development and recent progress. <i>World Journal of Gastroenterology</i> , 2014, 20, 3825.	3.3	53
56	Molecular classification of gastric cancers by parallel examination of multiple gene amplifications. <i>Journal of Clinical Oncology</i> , 2014, 32, 74-74.	1.6	0
57	Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report. <i>Tumori</i> , 2014, 100, e70-3.	1.1	1
58	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 1-6.	2.1	5
59	Su1976 A Molecular Classification of Gastric Cancers by Evaluation of Somatic Mutations and Gene Amplifications. <i>Gastroenterology</i> , 2013, 144, S-522.	1.3	0
60	The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Cancer Genetics</i> , 2013, 206, 26-31.	0.4	56
61	Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. <i>Analytical Biochemistry</i> , 2013, 433, 227-234.	2.4	90
62	Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC. <i>Neoplasma</i> , 2013, 60, 425-431.	1.6	8
63	Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. <i>Anticancer Research</i> , 2013, 33, 1705-11.	1.1	24
64	Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy. <i>Acta Cardiologica</i> , 2012, 67, 23-29.	0.9	22
65	Su1893 Circulating Free Tumor DNA as a Promising Marker for the Prediction of Survival and Monitoring of Remission in Colorectal Cancer After Radical Surgery. <i>Gastroenterology</i> , 2012, 142, S-529.	1.3	0
66	Options of genetic testing and methylation analysis of circulating free tumor DNA (tumor cell-free) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.0	0
67	Targeted therapy of EGFR mutated lung adenocarcinoma as neoadjuvant treatment followed lung resection—Case report. <i>Lung Cancer</i> , 2012, 77, S28.	2.0	0
68	Retreatment with erlotinib in NSCLC harboring EGFR mutation—Case report. <i>Lung Cancer</i> , 2012, 77, S29.	2.0	0
69	EGFR mutations in patients with advanced NSCLC. <i>Lung Cancer</i> , 2012, 77, S30.	2.0	0
70	Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. <i>Lung Cancer</i> , 2012, 77, S30.	2.0	1
71	Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. <i>Neoplasma</i> , 2012, 60, 26-32.	1.6	20
72	Second line treatment in advanced non-small cell lung cancer (NSCLC): Comparison of efficacy of Erlotinib and chemotherapy. <i>Neoplasma</i> , 2012, 60, 129-134.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Rapid testing of clopidogrel resistance by genotyping of <scp>CYP2C19</scp> and <scp>CYP2C9</scp> polymorphisms using denaturing on-chip capillary electrophoresis. <i>Electrophoresis</i> , 2012, 33, 1306-1310.	2.4	9
74	Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. <i>Anticancer Research</i> , 2012, 32, 1621-6.	1.1	18
75	9074 POSTER DNA Hypermethylation in Progressive Advanced Non Small Cell Lung Cancer. <i>European Journal of Cancer</i> , 2011, 47, S614.	2.8	0
76	Circulating Free Tumor DNA in Patient Plasma is a Near-Perfect Marker for Metastatic Spread of Colorectal Cancer: A Study on 165 Patients Undergoing Surgical Treatment. <i>Gastroenterology</i> , 2011, 140, S-343.	1.3	1
77	9093 POSTER The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors. <i>European Journal of Cancer</i> , 2011, 47, S620.	2.8	0
78	Molecular biology of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2011, 17, 2897.	3.3	69
79	A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. <i>Electrophoresis</i> , 2010, 31, 3518-3524.	2.4	10
80	Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy. <i>Journal of Separation Science</i> , 2010, 33, 2349-2355.	2.5	8
81	Assembly of a large Y-STR haplotype database for the Czech population and investigation of its substructure. <i>Forensic Science International: Genetics</i> , 2010, 4, e75-e78.	3.1	26
82	Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. <i>Anticancer Research</i> , 2010, 30, 1667-71.	1.1	50
83	Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 647-650.	0.7	6
84	Somatic <i>TP53</i> mutation mosaicism in a patient with Li-Fraumeni syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2009, 149A, 206-211.	1.2	29
85	Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. <i>Anticancer Research</i> , 2009, 29, 1803-10.	1.1	28
86	Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. <i>Anticancer Research</i> , 2009, 29, 2767-73.	1.1	25
87	Our initial experience with genetic testing of patients with hypertrophic cardiomyopathy: mutations of troponin T and troponin I genes. <i>Cor Et Vasa</i> , 2008, 50, 242-245.	0.1	0
88	D3-01: Genotyping single-nucleotide polymorphisms(SNP) in ERCC1, XPD, XRCC1, XRCC3 and MDR1 and CCND1 genes for response and toxicity prediction in chemotherapy of non small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S396-S397.	1.1	0
89	P3-131: Mutations of EGFR and ras oncogene as predictors of tyrosinkinase inhibitors therapeutic outcome in NSCLC patients. <i>Journal of Thoracic Oncology</i> , 2007, 2, S735.	1.1	0
90	106 A POLYMORPHISM IN 5-ALPHA-REDUCTASE (SRD5A2) GENE SHOWS NOVEL ASSOCIATION WITH PROSTATE CANCER. <i>European Urology Supplements</i> , 2007, 6, 49.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 3714.	3.3	95
92	Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. <i>Cancer Letters</i> , 2006, 242, 68-76.	7.2	12
93	Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. <i>Electrophoresis</i> , 2006, 27, 3856-3863.	2.4	3
94	Multicapillary electrophoresis of unlabeled DNA fragments with high-sensitive laser-induced fluorescence detection by counter-current migration of intercalation dye. <i>Electrophoresis</i> , 2005, 26, 4064-4069.	2.4	11
95	Application of cycling gradient capillary electrophoresis to detection of APC, K-ras, and DCC point mutations in patients with sporadic colorectal tumors. <i>Electrophoresis</i> , 2004, 25, 1016-1021.	2.4	12
96	Cycling gradient capillary electrophoresis: A low-cost tool for high-throughput analysis of genetic variations. <i>Electrophoresis</i> , 2003, 24, 1716-1722.	2.4	27
97	Application of high-resolution capillary array electrophoresis with automated fraction collection for GeneCalling [®] analysis of the yeast genomic DNA. <i>Electrophoresis</i> , 2003, 24, 639-647.	2.4	21
98	Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments. <i>Journal of Separation Science</i> , 2003, 26, 1163-1168.	2.5	16
99	Design of a fraction collector for capillary array electrophoresis. <i>Electrophoresis</i> , 2002, 23, 35.	2.4	31
100	Mutation Detection in KRAS Exon 1 by Constant Denaturant Capillary Electrophoresis in 96 Parallel Capillaries. <i>Analytical Biochemistry</i> , 2002, 304, 200-205.	2.4	24
101	Automated High-Throughput Infusion ESI-MS with Direct Coupling to a Microtiter Plate. <i>Analytical Chemistry</i> , 2001, 73, 1449-1454.	6.5	31
102	Fraction collection in micropreparative capillary zone electrophoresis and capillary isoelectric focusing. <i>Electrophoresis</i> , 2000, 21, 247-254.	2.4	65
103	Ultrafast DNA analysis by capillary electrophoresis/laser-induced fluorescence detection. <i>Electrophoresis</i> , 1998, 19, 1436-1444.	2.4	42
104	Size-based separation of polyelectrolytes by capillary zone electrophoresis: Migration regimes and selectivity of poly(styrenesulphonates) in solutions of derivatized cellulose. <i>Electrophoresis</i> , 1997, 18, 98-103.	2.4	20
105	Dispersion effects accompanying pressurized zone mobilisation in capillary isoelectric focusing of proteins. <i>Journal of Chromatography A</i> , 1996, 738, 123-128.	3.7	34
106	Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	0